Will depend on a number of things including dilution, IMO. The ideal will be debt (esp via offtake partner) and option to convert preference shares at a much higher price (CRPS)?
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025